Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 3/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6191591 | 1.00 | CHRNB4 (0.48) | CHRNB4CHRNA3ALDH1A1LMNAMAPT | |
| SCHEMBL9242426 | 0.88 | CHRNB4 (0.67) | CHRNB4CHRNA3ALOX5APFEN1 | |
| SCHEMBL4476971 | 0.88 | CHRNB4 (0.67) | CHRNB4CHRNA3ALOX5APFEN1 | |
| SCHEMBL4476967 | 0.88 | CHRNB4 (0.67) | CHRNB4CHRNA3ALOX5APFEN1 | |
| SCHEMBL25594933 | 0.85 | CHRNB4 (0.51) | CHRNB4CHRNA3LMNAALOX5APFEN1 | |
| SCHEMBL25594927 | 0.85 | CHRNB4 (0.51) | CHRNB4CHRNA3LMNAALOX5APFEN1 | |
| SCHEMBL4314692 | 0.85 | GPR119 (0.49) | CHRNB4CHRNA3ALOX5APFEN1GPR119 | |
| SCHEMBL2889380 | 0.85 | GPR119 (0.49) | CHRNB4CHRNA3ALOX5APFEN1GPR119 | |
| SCHEMBL6535537 | 0.85 | GPR119 (0.49) | LMNAALOX5APFEN1GPR119 | |
| SCHEMBL6535548 | 0.85 | GPR119 (0.49) | ALDH1A1ALOX5APFEN1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100400041-C | Diaminothiazoles useful as selective inhibitors of CDK4 | HOFFMANN LA ROCHE (CH) | 2008-07-09 | — | — | CN | disclosed |
| EP-1507530-B1 | DIAMINOTHIAZOLES AND USE THEREOF AS CDK4 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2005-11-02 | — | — | EP | disclosed |
| CN-1652780-A | Diaminothiazoles used as CDK4 inhibitors | HOFFMANN LA ROCHE (CH) | 2005-08-10 | — | — | CN | disclosed |
| EP-1507530-A1 | DIAMINOTHIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-23 | — | — | EP | disclosed |
| US-6818663-B2 | AS INHIBITORS OF CYCLIN-DEPENDENT KINASE 4 (CDK4); ANTIPROLIFERATIVE AGENTS; FOR THERAPY OF CANCER, TUMORS | HOFFMANN-LA ROCHES | 2004-11-16 | — | — | US | disclosed |
| US-20040006058-A1 | DIAMINOTHIAZOLES | CHU XIN-JIE (US) | 2004-01-08 | — | — | US | disclosed |
| WO-2003097048-A1 | DIAMINOTHIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006058-A1 | DIAMINOTHIAZOLES | CDK4, CDK1, CDK2 | CHRNB4 3974/4885CHRNA3 4386/4885ALDH1A1 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.